MedTrace Logo

A Study of Olverembatinib in the Treatment of Ph+ ALL

NCT05466175 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2022-09-01

No results posted yet for this study

Summary

In this study, adults with newly-diagnosed Philadelphia Chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) will receive first-line therapy of a novel third-generation TKI Olverembatinib.

The main purpose of the study is to evaluate the efficacy and safety of Olverembatinib in Ph+ ALL patients.

Conditions

  • Philadelphia-Positive ALL

Interventions

DRUG

Olverembatinib

Given PO

DRUG

Prednisone

Given Intravenous

DRUG

Vincristine

Given Intravenous

Sponsors & Collaborators

  • Chen Suning

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-01
Primary Completion
2023-09-30
Completion
2024-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05466175 on ClinicalTrials.gov